HEBRON FARMACEUTICA - PESQUISA,DESENVOLV – Trademark Portfolio

Entity Type: 16

HEBRON FARMACEUTICA - PESQUISA,DESENVOLV holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include HEBRON. The owner is based in SANTANA DE PARNAIBA, SAO PAULO.

DR. YOJIRO TAKAOKA AVE. 4384, LOJA 17

SANTANA DE PARNAIBA, SAO PAULO 06500-000 , BR

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

HEBRON
HEBRON
Registered 2012

Trademark Classifications

HEBRON FARMACEUTICA - PESQUISA,DESENVOLV's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does HEBRON FARMACEUTICA - PESQUISA,DESENVOLV have?

HEBRON FARMACEUTICA - PESQUISA,DESENVOLV has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does HEBRON FARMACEUTICA - PESQUISA,DESENVOLV file in?

HEBRON FARMACEUTICA - PESQUISA,DESENVOLV files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are HEBRON FARMACEUTICA - PESQUISA,DESENVOLV's most well-known trademarks?

HEBRON FARMACEUTICA - PESQUISA,DESENVOLV's registered trademark portfolio includes well-known marks such as HEBRON. These are among 1 currently registered trademark in the portfolio.

What is HEBRON FARMACEUTICA - PESQUISA,DESENVOLV's trademark registration success rate?

HEBRON FARMACEUTICA - PESQUISA,DESENVOLV has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.